Fmr LLC Viking Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 16,540,281 shares of VKTX stock, worth $1.21 Billion. This represents 0.06% of its overall portfolio holdings.

Number of Shares

16,540,281

Previous 16,347,292 1.18%

Holding current value

$1.21 Billion

Previous $1.34 Billion 34.59%

% of portfolio

0.06%

Previous 0.09%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $9.15 Million - $15.5 Million	192,989 Added 1.18%	16,540,281 $877 Million
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $23.4 Million - $127 Million	1,342,952 Added 8.95%	16,347,292 $1.34 Billion
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $147 - $314	16 Added 0.0%	15,004,340 $279 Million
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $311,405 - $456,272	28,517 Added 0.19%	15,004,324 $166 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $60.1 Million - $100 Million	4,053,059 Added 37.11%	14,975,807 $243 Million
Q1 2023 May 11, 2023	BUY	$8.08 - $17.33 $88.2 Million - $189 Million	10,920,979 Added 617353.25%	10,922,748 $182 Million
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $810 - $2,801	-298 Reduced 14.42%	1,769 $16,000
Q3 2022 Nov 10, 2022	SELL	$2.55 - $3.89 $79 - $120	-31 Reduced 1.48%	2,067 $6,000
Q2 2022 Aug 12, 2022	BUY	$2.11 - $3.15 $1,413 - $2,110	670 Added 46.92%	2,098 $6,000
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $4,074 - $6,627	1,358 Added 1940.0%	1,428 $4,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $50 - $73	11 Added 18.64%	70 $0
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $758 - $957	-136 Reduced 69.74%	59 $0
Q2 2021 Aug 13, 2021	BUY	$5.19 - $6.73 $1,012 - $1,312	195 New	195 $1,000

Others Institutions Holding VKTX

# of Institutions

462

Shares Held

65.9M

Call Options Held

6.24M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.59B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account